Abstract
This cross-sectional study determines the frequency of and rationale for US Food and Drug Administration (FDA) approval of drugs not meeting pivotal trial primary efficacy end points.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have